INSM insider trading
NasdaqGS HealthcareINSMED Inc: insider trade history from SEC Form 4 filings.
About INSMED Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Company website: www.insmed.com
INSM insider activity at a glance
FilingIQ tracks 1,158 insider transactions for INSM in filings since Jan 9, 2015. The most recent transaction is dated Sep 9, 2026.
Across the full history, 22 open-market purchases
and 605 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on INSM insider trades is 62.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest INSM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading INSM
13F funds holding INSM
Frequently asked
- How many insider trades does FilingIQ track for INSM?
- FilingIQ tracks 1,158 Form 4 insider transactions for INSM (INSMED Inc), covering filings from Jan 9, 2015 onwards. 19 of those are dated within the last 90 days.
- Are INSM insiders net buyers or net sellers?
- Across the full Form 4 history for INSM, 22 transactions (2%) were open-market purchases and 605 (52%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does INSM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is INSM in?
- INSMED Inc (INSM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $33.62B.
Methodology & sources
Every INSM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.